Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Marek, Diana ^a,b   Papin, Stephanie ^a   Ellefsen, Kim ^c   Niederhauser, Julien ^c   Isidor, Nathalie ^c   Ransijn, Adriana ^a   Poupon, Lucienne ^c   Spertini, Francois ^c   Pantaleo, Giuseppe ^c   Bergmann, Sven ^a,b   Beckmann, Jacques S ^a,c   Jacquemont, Sebastien ^c   Tanackovic, Goranka ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cytokines; Fragile X mental retardation 1 (FMR1) gene; Fragile X associated tremor ataxia syndrome; IL 10; Immune activation

Indexed keywords

CYTOSINE; GUANINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; ALLELE; ARTICLE; ASYMPTOMATIC DISEASE; ATAXIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRAGILE X MENTAL RETARDATION 1 GENE; FRAGILE X SYNDROME; GENE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; MALE; MENTAL DEFICIENCY; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 84867289265     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-238     Document Type: Article

References (35)

1. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003, 72:869-878. 10.1086/374321, 1180350, 12638084.
2. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman RJ. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008, 146A:1009-1016. 10.1002/ajmg.a.32060, 2888464, 18348275.
3. Gleicher N, Weghofer A, Lee IH, Barad DH. FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS One 2010, 5:e15303. 10.1371/journal.pone.0015303, 3002956, 21179569.
4. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010, 19:R83-R89. 10.1093/hmg/ddq166, 2875053, 20430935.
5. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 2002, 12:278-283. 10.1016/S0959-437X(02)00299-X, 12076670.
6. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130. 10.1212/WNL.57.1.127, 11445641.
7. Hessl D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, Barbato I, Rice C, Gould E, Hall DA, Grigsby J, Wegelin JA, Harris S, Lewin F, Weinberg D, Hagerman PJ, Hagerman RJ. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 2005, 139B:115-121. 10.1002/ajmg.b.30241, 16184602.
8. Tassone F, Hagerman RJ, Garcia-Arocena D, Khandjian EW, Greco CM, Hagerman PJ. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet 2004, 41:e43. 10.1136/jmg.2003.012518, 1735735, 15060119.
9. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, 125:1760-1771. 10.1093/brain/awf184, 12135967.
10. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, Babineau B, Lebrilla CB, Hagerman RJ, Hagerman PJ. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006, 129:256-271.
11. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 2007, 20:351-357. 10.1097/WCO.0b013e3280adc943, 17495632.
12. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7. 10.1124/jpet.102.035048, 12490568.
13. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28:7687-7698. 10.1523/JNEUROSCI.0143-07.2008, 2702093, 18650345.
14. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006, 29:518-527. 10.1016/j.tins.2006.07.006, 16879881.
15. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003, 24:395-401. 10.1016/S0165-6147(03)00176-7, 12915048.
16. Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000, 293:607-617.
17. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
18. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Hong JS, Liu B. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004, 18:589-591.
19. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal anti-inflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005, 58:963-967. 10.1002/ana.20682, 16240369.
20. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011, 76:863-869. 10.1212/WNL.0b013e31820f2d79, 3059148, 21368281.
21. McGeer EG, McGeer PL. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007, 21:789-797. 10.2165/00023210-200721100-00001, 17850169.
22. Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. Trends Pharmacol Sci 2007, 28:536-543. 10.1016/j.tips.2007.09.004, 17900710.
23. Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008, 70:1397-1402. 10.1212/01.wnl.0000281692.98200.f5, 2685188, 18057320.
24. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011, 72:175-182. 10.4088/JCP.09m05407blu, 20816038.
25. Kogan CS, Turk J, Hagerman RJ, Cornish KM. Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:859-872. 10.1002/ajmg.b.30685, 18165971.
26. Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008, 205:1869-1877. 10.1084/jem.20080178, 2525598, 18625748.
27. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009, 119:332-337.
28. Roze E, Bonnet C, Betuing S, Caboche J. Huntington's disease. Adv Exp Med Biol 2010, 685:45-63. 10.1007/978-1-4419-6448-9_5, 23166927.
29. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47. 10.1186/1750-1326-4-47, 2784760, 19917131.
30. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005, 18:315-321. 10.1097/01.wco.0000169752.54191.97, 15891419.
31. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008, 223:114-131. 10.1111/j.1600-065X.2008.00635.x, 18613832.
32. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 2007, 7:425-428. 10.1038/nri2097, 17525751.
33. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181. 10.1038/nri2711, 20154735.
34. Hmadcha A, De Diego Y, Pintado E. Assessment of FMR1 expression by reverse transcriptase-polymerase chain reaction of KH domains. J Lab Clin Med 1998, 131:170-173. 10.1016/S0022-2143(98)90160-3, 9488501.
35. Dace DS, Khan AA, Stark JL, Kelly J, Cross AH, Apte RS. Interleukin-10 overexpression promotes Fas-ligand-dependent chronic macrophage-mediated demyelinating polyneuropathy. PLoS One 2009, 4:e7121. 10.1371/journal.pone.0007121, 2743195, 19771172.